Elena Núñez-Gómez

Elena Núñez-Gómez

Auto-generated profile, based on publicly available information

Elena Núñez-Gómez

Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2020 in Angiogenesis
Verified
Journal Article
Open access
PDF file
COClaudia Ollauri-Ibáñez
Claudia Ollauri-Ibáñez
ENElena Núñez-Gómez
Elena Núñez-Gómez
CECristina Egido-Turrión
Cristina Egido-Turrión
LSLaura Silva-Sousa
Laura Silva-Sousa
EDElena Diaz-Rodriguez
Elena Diaz-Rodriguez
MPMiguel Pericacho
Miguel Pericacho
Endoglin (CD105) is an auxiliary receptor for members of the TFG-β superfamily. Whereas it has been demonstrated that the deficiency of endoglin leads to minor and defective angiogenesis, little is known about the effect of its increased expression, characteristic of several types of cancer. Angiogenesis is essential for tumor growth, so high levels of proangiogenic molecules, such as endoglin, are supposed to be related to greater tumor growth leading to a poor cancer prognosis. However, we demonstrate here that endoglin overexpression do not stimulate sprouting or vascularization in several in vitro and in vivo models. Instead, steady endoglin overexpression keep endothelial cells in an active phenotype that results in an impairment of the correct stabilization of the endothelium and the recruitment of mural cells. In a context of continuous enhanced angiogenesis, such as in tumors, endoglin overexpression gives rise to altered vessels with an incomplete mural coverage that permit the extravasation of blood. Moreover, these alterations allow the intravasation of tumor cells, the subsequent development of metastases and, thus, a worse cancer prognosis.

Verified
Journal Article
Open access
PDF file
LPLucía Pérez-Roque
Lucía Pérez-Roque
ENElena Núñez-Gómez
Elena Núñez-Gómez
ARAlicia Rodriguez-Barbero
Alicia Rodriguez-Barbero
Carmelo BernabeuCarmelo Bernabeu
Carmelo Bernabeu
JLJosé M Lopez-Novoa
José M Lopez-Novoa
MPMiguel Pericacho
Miguel Pericacho
Preeclampsia is a pregnancy-specific disease of high prevalence characterized by the onset of hypertension, among other maternal or fetal signs. Its etiopathogenesis remains elusive, but it is widely accepted that abnormal placentation results in the release of soluble factors that cause the clinical manifestations of the disease. An increased level of soluble endoglin (sEng) in plasma has been proposed to be an early diagnostic and prognostic biomarker of this disease. A pathogenic function of sEng involving hypertension has also been reported in several animal models with high levels of plasma sEng not directly dependent on pregnancy. The aim of this work was to study the functional effect of high plasma levels of sEng in the pathophysiology of preeclampsia in a model of pregnant mice, in which the levels of sEng in the maternal blood during pregnancy replicate the conditions of human preeclampsia. Our results show that wild type pregnant mice carrying human sEng-expressing transgenic fetuses (fWT(hsEng+)) present high plasma levels of sEng with a timing profile similar to that of human preeclampsia. High plasma levels of human sEng (hsEng) are associated with hypertension, proteinuria, fetal growth restriction, and the release of soluble factors to maternal plasma. In addition, fWT(hsEng+) mice also present placental alterations comparable to those caused by the poor remodeling of the spiral arteries characteristic of preeclampsia. In vitro and ex vivo experiments, performed in a human trophoblast cell line and human placental explants, show that sEng interferes with trophoblast invasion and the associated pseudovasculogenesis, a process by which cytotrophoblasts switch from an epithelial to an endothelial phenotype, both events being related to remodeling of the spiral arteries. Our findings provide a novel and useful animal model for future research in preeclampsia and reveal a much more relevant role of sEng in preeclampsia than initially proposed.

3 July 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
COClaudia Ollauri-Ibáñez
Claudia Ollauri-Ibáñez
ENElena Núñez-Gómez
Elena Núñez-Gómez
CECristina Egido-Turrión
Cristina Egido-Turrión
LSLaura Silva-Sousa
Laura Silva-Sousa
ARAlicia Rodriguez-Barbero
Alicia Rodriguez-Barbero
MPMiguel Pericacho
Miguel Pericacho
Angiogenesis is a complex process essential for tumor growth. For this reason, high levels of pro-angiogenic molecules, such as endoglin (CD105), are supposed to be related to greater tumor growth that lead to a poor cancer prognosis. However, we demonstrate here that defects in angiogenesis that can be attributed to high levels of endoglin, lead to development and worsening of cancer disease. Steady endoglin overexpression disrupts the correct stabilization of the endothelium and the recruitment of mural cells. In consequence, endoglin overexpression gives rise to altered vessels that promote the intravasation of tumor cells, the subsequent development of metastases and, thus, a worse cancer prognosis.